Eric Schmidt

2021

In 2021, Eric Schmidt earned a total compensation of $3.5M as Chief Financial Officer at Allogene Therapeutics, a 39% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$180,500
Option Awards$1,963,489
Salary$475,000
Stock Awards$839,973
Total$3,458,962

Schmidt received $2M in option awards, accounting for 57% of the total pay in 2021.

Schmidt also received $180.5K in non-equity incentive plan, $475K in salary and $840K in stock awards.

Rankings

In 2021, Eric Schmidt's compensation ranked 3,874th out of 12,415 executives tracked by ExecPay. In other words, Schmidt earned more than 68.8% of executives.

ClassificationRankingPercentile
All
3,874
out of 12,415
69th
Division
Manufacturing
1,587
out of 5,505
71st
Major group
Chemicals And Allied Products
650
out of 2,375
73rd
Industry group
Drugs
578
out of 2,096
72nd
Industry
Biological Products, Except Diagnostic Substances
153
out of 449
66th
Source: SEC filing on April 26, 2022.

Schmidt's colleagues

We found four more compensation records of executives who worked with Eric Schmidt at Allogene Therapeutics in 2021.

2021

David Chang

Allogene Therapeutics

Chief Executive Officer

2021

Rafael Amado

Allogene Therapeutics

Chief Medical Officer

2021

Alison Moore

Allogene Therapeutics

Chief Technical Officer

2021

Veer Bhavnagri

Allogene Therapeutics

General Counsel

News

In-depth

You may also like